Johnson & Johnson: Expect Underwhelming Results To Continue
JNJ dipped after underwhelming guidance for 2018.
The stock has lagged the market rally due to a stretched valuation and limited growth.
The lack of additional capital returns is a negative signal for the stock.
Despite the gains of the last year,Johnson & Johnson(JNJ) hasn't actually outperformed the market. In fact, the stock has now vastly underperformed the market since the start of November and reinforces thevaluation questionsthat exist with this healthcare stock and ongoing negative signals from the company.